Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2024-09-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于CFT8919胶囊获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Betta Pharmaceuticals Co., Ltd. regarding the approval of clinical trial notification for the drug CFT8919 capsules by the National Medical Products Administration (NMPA). It details the clinical trial approval, drug background, licensing agreement, and potential impact on the company. The document is short (1594 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it does not mention the release or availability of a report. It is a regulatory announcement about a clinical trial approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-09-19 Chinese
关于召开2024年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2024 second extraordinary general meeting of shareholders for Betta Pharmaceuticals Co., Ltd. It includes information about the meeting date, voting procedures, proposal details, registration, and attachments such as proxy forms and voting instructions. There is no financial data, earnings, audit information, or management discussion. The document is not a report but a formal announcement and invitation to a shareholders meeting with voting instructions. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings.
2024-09-19 Chinese
关于补选第四届董事会非独立董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of a new non-independent director to the company's board, including details about the nominee's background and qualifications. It references compliance with company law and stock exchange regulations, and it is clearly about changes in the board of directors. There is no financial data or report content, only a formal announcement of a board member change.
2024-09-19 Chinese
关于与武汉禾元生物科技股份有限公司签署《药品区域经销协议》暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about a commercial cooperation agreement between the company 贝达药业 and an affiliated company 武汉禾元生物科技股份有限公司. It discusses the signing of a regional drug distribution agreement, the nature of the transaction as a related party transaction, the financial and operational background of the counterparty, the pricing policy, the main content of the agreement, the purpose and impact on the company, risk warnings, and approvals by the board and independent directors. There are no financial statements or quarterly/yearly financial results presented. The document is not an earnings release, annual report, or interim report. It is not a call transcript or a remuneration report. It is a regulatory announcement about a related party transaction and a commercial agreement. The document length is about 4406 characters, which is relatively short and typical for a regulatory announcement. It does not contain the actual report but the announcement of a transaction and related disclosures. Therefore, the best fitting category is Regulatory Filings (RNS).
2024-09-19 Chinese
关于公司董事、高级管理人员离职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director and senior management personnel, detailing the resignation, its effective date, and the impact on the board and company operations. It includes information about shareholdings and compliance with relevant laws. There is no financial data, report, or presentation content. This fits the category of Board/Management Information (MANG). The document length is short and focused solely on management changes, confirming the classification.
2024-09-13 Chinese
关于注射用MCLA-129药物临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about the acceptance of a clinical trial application for a drug by the National Medical Products Administration (NMPA). It details the drug's characteristics, regulatory acceptance, and potential impact on the company. The document is short (1535 characters) and serves as an official notice rather than a detailed report or financial statement. It does not contain financial data, management discussion, or regulatory certifications. It is an announcement of a regulatory event related to clinical trial approval, which fits best under Regulatory Filings (RNS) as it does not match other specific categories like Annual Report, Earnings Release, or Legal Proceedings. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-09-10 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.